42 terminated. 42 Phase 2, 24 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Terminated 42 |
| Phase 1 | 24 | Terminated 24 |
Follow avelumab: new trials by email Literature Review of avelumab trials Research Report on avelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Axitinib, Avelumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2022-11-04 | 2023-05-03 |
| Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2022-08-10 | 2024-12-30 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab Trilaciclib, Gemcitabine, Cisplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | G1 Therapeutics, Inc. | 92 | 2021-06-04 | 2025-09-08 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers OC-001, Drug: OC-001 in Combination with Avelumab - Cancer, Neoplasms | Phase 1 / Phase 2 | Terminated | Ocellaris Pharma, Inc. | 73 | 2020-09-24 | 2026-01-12 |
| Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma rhIL-15, Avelumab - Clear-Cell Renal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2020-05-26 | 2022-05-17 |
| Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Pembrolizumab, Atezolizumab, Durvalumab - Urothelial Carcinoma | Phase 2 | Terminated | Case Comprehensive Cancer Center | 4 | 2020-03-23 | 2025-02-25 |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy Avelumab, N-803, haNK™ - Merkel Cell Carcinoma | Phase 2 | Terminated | ImmunityBio, Inc. | 9 | 2020-02-19 | 2024-08-09 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Avelumab, External beam radiotherapy - Myeloma, Multiple, Myeloma-Multiple | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2019-10-17 | 2021-05-12 |
| Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab - Other Skin | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2019-07-03 | 2025-03-06 |
| The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy Avelumab and Radical radiotherapy - Squamous Cell Carcinoma of the Skin | Phase 2 | Terminated | AHS Cancer Control Alberta | 8 | 2019-04-12 | 2025-06-27 |
| Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Avelumab, 2nd generation ADT (abiraterone or enzalutamide) - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Terminated | Jodi Layton, MD | 8 | 2019-01-25 | 2024-07-09 |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Avelumab - Bladder Cancer, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 1 | 2018-12-14 | 2020-08-24 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer Avelumab, Radiation - Bladder Cancer, Muscle Invasive Bladder Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 14 | 2018-12-13 | 2025-10-31 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Aldoxorubicin Hydrochloride, ALT-803, ETBX-011 - Colorectal Cancer Metastatic, mCRC | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 2 | 2018-09-28 | 2024-12-11 |
| A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Avelumab, Binimetinib, Talazoparib - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 36 | 2018-08-15 | 2022-01-26 |
| QUILT-3.080: NANT Pancreatic Cancer Vaccine Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 3 | 2018-07-17 | 2024-08-27 |
| Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Avelumab, Talazoparib - Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 | Phase 2 | Terminated | Pfizer | 202 | 2018-06-18 | 2023-09-25 |
Showing 20 of 42. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Urinary Bladder Neoplasms (9) · Carcinoma, Merkel Cell (5) · Pancreatic Neoplasms (5) · Carcinoma, Renal Cell (3) · Carcinoma, Transitional Cell (3) · Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Squamous Cell (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2)
Pfizer (9) · ImmunityBio, Inc. (8) · Fred Hutchinson Cancer Center (3) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · University of Texas Southwestern Medical Center (2) · AHS Cancer Control Alberta (1) · Andrew Sharabi (1) · Ariceum Therapeutics GmbH (1) · Assuntina Sacco, M.D. (1) · Baylor College of Medicine (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · G1 Therapeutics, Inc. (1) · Jodi Layton, MD (1)
United States (39) · Spain (7) · Australia (6) · Canada (5) · Belgium (4) · France (4) · Hungary (4) · Japan (4) · South Korea (4) · United Kingdom (4) · Italy (3) · Poland (3) · Denmark (2) · Russia (2) · Taiwan (2)
Andrew Sharabi, M.D., Ph.D. (1) · Assuntina Sacco, MD (1) · Aude Chapuis (1) · Bobby Reddy, MD (1) · Dana Cardin, M.D. (1) · David Hsieh, MD (1) · Jennifer M. Taylor, MD (1) · Jodi L Layton, MD (1) · John Walker, Walker (1) · Joshua Veatch (1) · Julius Y Strauss, M.D. (1) · Kent Mouw, MD, PhD (1)
PMID 32379297, PMID 32508818, PMID 32620210, PMID 35307972, PMID 36210487, PMID 36394849, PMID 36394867, PMID 37141847, PMID 37379764, PMID 38669053, PMID 39034968, PMID 40580957, PMID 42715345
2017 (5), 2015 (2), 2018 (2), P30CA015704 (2), 2019 (1), K24CA139052 (1), P01CA225517 (1), P30CA016672 (1), R01CA176841 (1), R01CA181450 (1)